Compare Bristol-Myers Squibb Co (BMY) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Vanguard S&P 500 ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.73 (market cap $129.94B), while Vanguard S&P 500 ETF trades at $710.04. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Vanguard S&P 500 ETF pays none. Which is the better fit depends on your goals.
| BMY | VOO | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $65.89 | $710.71 |
52-Week Low | $42.60 | $580.93 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
VOO trades at $710.44, down slightly by 0.02% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF is near record highs amid strong S&P 500 performance, supported by AI-driven earnings growth and institutional inflows. Recent dividend activity includes a $1.96 distribution scheduled for June 2026.
Outlook remains positive due to robust corporate earnings and upward analyst targets, but risks include high valuations and potential market pullbacks. Investors benefit from broad market exposure, though caution is warranted given elevated sentiment and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
